Fulgent Genetic (NASDAQ:FLGT) has earned an average broker rating score of 1.50 (Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company.
Analysts have set a 1-year consensus target price of $10.75 for the company, according to Zacks. Zacks has also assigned Fulgent Genetic an industry rank of 123 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research raised Fulgent Genetic from a “sell” rating to a “hold” rating in a report on Monday, July 10th.
In other news, insider Ming Hsieh acquired 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 15th. The stock was bought at an average price of $5.26 per share, with a total value of $105,200.00. Following the acquisition, the insider now owns 6,482,244 shares in the company, valued at approximately $34,096,603.44. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Large investors have recently made changes to their positions in the company. Scholtz & Company LLC raised its position in Fulgent Genetic by 50.3% in the first quarter. Scholtz & Company LLC now owns 266,705 shares of the company’s stock worth $2,912,000 after buying an additional 89,205 shares during the last quarter. William Blair Investment Management LLC bought a new position in Fulgent Genetic during the first quarter worth $6,330,000. Blair William & Co. IL bought a new position in Fulgent Genetic during the first quarter worth $287,000. Bank of New York Mellon Corp bought a new position in Fulgent Genetic during the first quarter worth $122,000. Finally, Wells Fargo & Company MN raised its position in Fulgent Genetic by 2,046.0% in the first quarter. Wells Fargo & Company MN now owns 10,730 shares of the company’s stock worth $118,000 after buying an additional 10,230 shares during the last quarter. 19.78% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Zacks: Fulgent Genetic (NASDAQ:FLGT) Receives Consensus Rating of “Buy” from Analysts” was published by BBNS and is owned by of BBNS. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://baseballnewssource.com/markets/zacks-fulgent-genetic-nasdaqflgt-receives-consensus-rating-of-buy-from-analysts-updated-updated/1315607.html.
Fulgent Genetic (NASDAQ:FLGT) traded down 1.96% during trading on Monday, hitting $6.49. 74,687 shares of the company traded hands. The company’s market capitalization is $114.82 million. The stock has a 50 day moving average price of $6.27 and a 200 day moving average price of $9.37. Fulgent Genetic has a 12-month low of $4.49 and a 12-month high of $13.90.
Fulgent Genetic (NASDAQ:FLGT) last announced its quarterly earnings data on Monday, May 8th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by $0.01. The company had revenue of $5.31 million during the quarter, compared to the consensus estimate of $5.85 million. On average, equities analysts anticipate that Fulgent Genetic will post $0.16 earnings per share for the current year.
Fulgent Genetic Company Profile
Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fulgent Genetic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetic and related companies with our FREE daily email newsletter.